Pembrolizumab 200 mg
3475-799
Phase 2 small_molecule completed
Quick answer
Pembrolizumab 200 mg for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed